$6.92
1.02% yesterday
Nasdaq, Jul 17, 10:04 pm CET
ISIN
US1374041093
Symbol
CADL

Candel Therapeutics Inc Stock price

$6.92
+1.98 40.08% 1M
+0.26 3.83% 6M
-1.76 20.28% YTD
+0.35 5.33% 1Y
+3.50 102.34% 3Y
-0.08 1.14% 5Y
-0.08 1.14% 10Y
-0.08 1.14% 20Y
Nasdaq, Closing price Thu, Jul 17 2025
+0.07 1.02%
ISIN
US1374041093
Symbol
CADL
Sector
Industry

Key metrics

Basic
Market capitalization
$369.0m
Enterprise Value
$286.9m
Net debt
positive
Cash
$92.2m
Shares outstanding
49.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.9
Financial Health
Equity Ratio
62.1%
Return on Equity
-83.2%
ROCE
-44.3%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-32.6m | $-39.3m
EBIT
$-33.6m | $-39.9m
Net Income
$-39.6m | $-41.1m
Free Cash Flow
$-27.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
8.7% | -21.5%
EBIT
8.3% | -19.6%
Net Income
-5.9% | 25.5%
Free Cash Flow
15.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
16.2%
Employees
42
Rev per Employee
$0.0
Show more

Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Candel Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Candel Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
6% 6%
-
- Research and Development Expense 18 18
16% 16%
-
-33 -33
9% 9%
-
- Depreciation and Amortization 1.01 1.01
4% 4%
-
EBIT (Operating Income) EBIT -34 -34
8% 8%
-
Net Profit -40 -40
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Candel Therapeutics Inc Stock News

Positive
Proactive Investors
9 days ago
Candel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective with the opening of the US markets on June 30.
Neutral
GlobeNewsWire
9 days ago
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company was added to multiple Russell indexes as part of the 2025 Russell US Indexes annual reconstitution, which became e...
Positive
Proactive Investors
24 days ago
Candel Therapeutics Inc (NASDAQ:CADL) has announced a $15 million registered direct offering of common stock, the proceeds of which will support launch readiness, medical affairs, and pre-commercialization activities, as well as preparation for a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer, expected in the fourth quarter of 2026. “We are pleased to strengthen ...
More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office United States
CEO Paul-Peter Tak
Employees 42
Founded 2002
Website www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today